Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) EPS (Weighted Average and Diluted) (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.65 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 64.29% year-over-year to -$0.65; the TTM value through Dec 2025 reached -$1.68, up 88.63%, while the annual FY2025 figure was -$1.68, 88.63% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.65 in Q4 2025 per VRCA's latest filing, down from -$0.02 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.04 in Q3 2022 and bottomed at -$7.63 in Q2 2024.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$1.05, with a median of -$0.43 recorded in 2021.
  • Peak YoY movement for EPS (Weighted Average and Diluted): surged 107.66% in 2022, then tumbled 3079.17% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.35 in 2021, then soared by 60.0% to -$0.14 in 2022, then plummeted by 285.71% to -$0.54 in 2023, then tumbled by 237.04% to -$1.82 in 2024, then skyrocketed by 64.29% to -$0.65 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.65 in Q4 2025, -$0.02 in Q3 2025, and -$0.91 in Q2 2025.